Dr. Patrick Hauswirth

Persönliches Profil

Tätigkeit an der ZHAW

Wissenschaftlicher Mitarbeiter

www.zhaw.ch/de/lsfm/institute-zentren/icbt/pharmazeutische-wirkstoffforschung-und-arzneimittelentwicklung/pharmazeutische-technologie-und-pharmakologie/

Arbeits- und Forschungsschwerpunkte, Spezialkenntnisse

Drug targeting and delivery
Drug formulations
Zebrafish embryo based drug screening models
Lipid nanoparticles, liposomes and extracellular vesicles for drug delivery
Cancer gene therapy
Genetics

Aus- und Fortbildung

PhD in pharmaceutical technology; PhD project 'Design and delivery of genes encoding oncotoxic proteins for cancer treatment' at the University of Basel

MSc in molecular biology; Master's thesis project 'Characterization of the KCNH2 potassium channel' at F. Hoffman la Roche and the University of Basel

Publikationen vor Tätigkeit an der ZHAW

Hauswirth, P.; Graber, P.; Buczak, K.; Mancuso, R.V.; Schenk, S.H.; Nüesch, J.P.F.; Huwyler, J. Design and Characterization of Mutated Variants of the Oncotoxic Parvoviral Protein NS1. Viruses 2023, 15, 209. doi.org/10.3390/v15010209

Pratsinis A, Uhl P, Bolten JS, Hauswirth P, Schenk SH, Urban S, Mier W, Witzigmann D, Huwyler J. Virus-Derived Peptides for Hepatic Enzyme Delivery. Mol Pharm. 2021 May 3;18(5):2004-2014. doi.org/10.1021/acs.molpharmaceut.0c01222

Witzigmann D, Grossen P, Quintavalle C, Lanzafame M, Schenk SH, Tran XT, Englinger B, Hauswirth P, Grünig D, van Schoonhoven S, Krähenbühl S, Terracciano LM, Berger W, Piscuoglio S, Quagliata L, Rommelaere J, Nüesch JPF, Huwyler J. Non-viral gene delivery of the oncotoxic protein NS1 for treatment of hepatocellular carcinoma. J Control Release. 2021 Jun 10;334:138-152. doi.org/10.1016/j.jconrel.2021.04.023

Zurück